Full Breakdown
Oral GLP-1 Pill Maintains Weight Loss After Injectable Therapy, Late-Stage Trial Shows
5/13/2026, 12:00:03 PM
Oral Pill Demonstrates Weight-Loss Maintenance in Late-Stage Trial
A year-long, double-blind study (ATTAIN-MAINTAIN) evaluated the oral GLP-1 medication orforglipron, marketed as Foundayo, in participants who had previously lost weight on injectable GLP-1 drugs. After switching to the daily pill, patients retained more than 70 % of their prior loss, compared with 38-50 % in the placebo arm. Those previously on tirzepatide (Zepbound/Mounjaro) kept 74.7 % of weight loss versus 49.2 % on placebo; prior semaglutide (Wegovy) users kept 79.3 % versus 37.6 % on placebo. Average regain was 0.9 kg for Wegovy switchers and about 5 kg for Zepbound switchers.
Study Design, Participants, and Context
The trial enrolled 376 U.S. adults who had completed at least 72 weeks on high-dose injectables (tirzepatide, semaglutide, or Ozempic) and achieved clinically meaningful weight loss. Participants were randomized to daily orforglipron or matching placebo for 52 weeks. The research, funded by Eli Lilly, was presented at the European Congress on Obesity in Istanbul. Oral GLP-1 options are emerging as alternatives for patients averse to injections; the World Health Organization has labeled obesity a global public-health crisis, and analysts project weight-loss drug sales to exceed $100 billion annually.
Quantitative Outcomes
- Weight retention: >70 % (overall) vs 38-50 % (placebo).
- Tirzepatide subgroup: 74.7 % vs 49.2 %.
- Semaglutide subgroup: 79.3 % vs 37.6 %.
- Weight regain: 0.9 kg (Wegovy switch) vs ~5 kg (Zepbound switch).
- Adverse events: Nausea, constipation, diarrhoea; nausea reported in 18.8 % of oral-treatment participants.
- Metabolic markers: Reductions in blood pressure, lipids, and glucose observed in the oral-treatment arm were maintained.
- Cost context: In the United States, the oral pill is priced around $149 per month, markedly lower than >$1,000 per month for some injectable GLP-1 products.
Clinical and Market Implications
The findings suggest an oral maintenance option can preserve most weight loss achieved with injectable induction, potentially expanding treatment to needle-averse patients and simplifying long-term therapy. Sustained metabolic improvements may lower obesity-related cardiovascular risk. Payer policies and step-therapy sequencing could shift if regulators endorse a maintenance indication.
Official Statements
Eli Lilly’s Kenneth Custer emphasized that patients “can switch from a GLP-1 injectable to a GLP-1 pill and basically keep all the weight off,” adding that “patients now have options.” Dr Simon Cork (Anglia Ruskin University) called the trial “a really important study” addressing the rebound problem after stopping injectables. Dr Marie Spreckley (University of Cambridge) noted the study reinforces the view of obesity as a chronic, relapsing disease requiring ongoing treatment.
Criticisms and Limitations
The trial was industry-funded and limited to individuals who had already succeeded on injectables, restricting generalizability to treatment-naïve patients. Follow-up was limited to one year, leaving long-term durability uncertain. Side-effect rates, while mild, were not negligible. Pricing in the United Kingdom remains undisclosed, and regulatory approval for a maintenance label is pending.
Conflicting Figures & Data Gaps
Reported weight-retention percentages vary across sources (70 % overall vs 74.7 % and 79.3 % for specific subgroups), reflecting different subgroup analyses. The exact magnitude of weight regain for Zepbound switchers is consistently cited as “about 5 kg,” but precise confidence intervals are not provided. Long-term safety beyond 52 weeks remains unreported.
Verbatim Quotes
- “If you're a patient on Wegovy, you can switch from a GLP-1 injectable to a GLP-1 pill and basically keep all the weight off,” — Kenneth Custer, President of Cardiometabolic Health, Eli Lilly
- “Patients now have options.” — Kenneth Custer, Eli Lilly
- “Dr Simon Cork from Anglia Ruskin University says it is a "really important study" that addresses a key limitation with injectable, GLP-1 based weight loss medications – that patients experience significant weight rebound after stopping them.” — Dr Simon Cork, Anglia Ruskin University
- “We still do not know how durable these effects will be over longer periods of time.” — Dr Marie Spreckley, University of Cambridge
- “If you want to maintain every ounce of weight you lost on a drug like Zepbound, you should probably stay on that dose of Zepbound," Custer said.” — Kenneth Custer, Eli Lilly
- “But if you want to consider reducing your dose, you can do that. You'll regain a little bit of weight, but you'll still maintain most of your weight loss,” — Kenneth Custer, Eli Lilly
Upcoming Regulatory Steps
The next milestone is FDA review of ATTAIN-MAINTAIN data to determine whether a formal maintenance indication will be granted for orforglipron. Approval could dictate step-therapy criteria and influence reimbursement decisions in the United States and, subsequently, in other markets such as the United Kingdom. Further peer-reviewed publication and longer-term extension studies are anticipated to clarify durability and safety.
